Clinical Trial Update: Use of Long-Acting Injectable Cabotegravir/Rilpivirine for the Treatment of HIV in Belgium

View source ↗

Summary

Belgian researchers are recruiting for a trial evaluating the long-acting injectable cabotegravir/rilpivirine for HIV treatment (Cabenuva) in Belgium.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• CABENUVA (cabotegravir and rilpivirine)

Snippet

Sponsor: Belgian Research on AIDS and HIV Consortium | Conditions: Human Immunodeficiency Virus | Status: RECRUITING